Bampidis Vasileios, Azimonti Giovanna, Bastos Maria de Lourdes, Christensen Henrik, Dusemund Birgit, Durjava Mojca Fašmon, Kouba Maryline, López-Alonso Marta, López Puente Secundino, Marcon Francesca, Mayo Baltasar, Pechová Alena, Petkova Mariana, Ramos Fernando, Sanz Yolanda, Villa Roberto Edoardo, Woutersen Ruud, Aquilina Gabriele, Bories Georges, Brantom Paul, Cocconcelli Pier Sandro, Gropp Jürgen, Rychen Guido, Holczknecht Orsolya, Vettori Maria Vittoria
EFSA J. 2021 Mar 22;19(3):e06466. doi: 10.2903/j.efsa.2021.6466. eCollection 2021 Mar.
Following a request from the European Commission, the Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the coccidiostat Nilablend™ 200G containing lasalocid A sodium and nicarbazin. Nilablend™ 200G is not safe for chickens for fattening at the proposed maximum use level of 50 mg lasalocid A sodium + 50 mg nicarbazin/kg complete feed. Concurrent administration of Nilablend™ 200G (containing lasalocid A sodium) with tiamulin and certain other medicinal substances should be avoided. Lasalocid A sodium has antimicrobial activity against Gram-positive bacterial species while many Enterobacteriaceae are naturally resistant. Induction of resistance and/or cross-resistance was not observed in experimental conditions. No information on the interactions of nicarbazin with feed materials, other approved additives or medicinal products have been provided. No data were submitted on the microbiological safety of nicarbazin. The toxicological package for lasalocid A sodium and nicarbazin identified no observed adverse effect levels (NOAELs) that could be the basis for setting health-based guidance values (e.g. an acceptable daily intake (ADI)). The Panel concluded that a concern for the genotoxicity of nicarbazin in Nilablend™ 200G cannot be excluded and that clarification on the mechanism of action of the test items would be needed. Therefore, the FEEDAP Panel is not in the position to establish an ADI for DNC on which to base the assessment of consumer safety. Nilablend™ 200G is considered toxic by inhalation, corrosive and irritant to eyes, slightly irritant to the skin but not a skin sensitiser. Inhalation exposure is considered a risk to persons handling the additive. The FEEDAP Panel cannot conclude on the safety of Nilablend™ 200G for the environment due to a possible risk for aquatic compartment (freshwater) for DNC. The efficacy of Nilablend 200G was demonstrated.
应欧盟委员会的要求,动物饲料添加剂及产品或物质专家小组(FEEDAP)被要求就含有拉沙洛西钠和尼卡巴嗪的抗球虫药Nilablend™ 200G发表科学意见。对于育肥鸡,以建议的最大使用水平50毫克拉沙洛西钠+50毫克尼卡巴嗪/千克全价饲料使用Nilablend™ 200G不安全。应避免Nilablend™ 200G(含拉沙洛西钠)与替米考星及某些其他药物同时使用。拉沙洛西钠对革兰氏阳性菌具有抗菌活性,而许多肠杆菌科细菌天然耐药。在实验条件下未观察到耐药性和/或交叉耐药性的诱导。未提供关于尼卡巴嗪与饲料原料、其他批准的添加剂或药品相互作用的信息。未提交关于尼卡巴嗪微生物安全性的数据。拉沙洛西钠和尼卡巴嗪的毒理学资料未确定可作为设定基于健康的指导值(如每日允许摄入量(ADI))依据的未观察到有害作用水平(NOAEL)。专家小组得出结论,不能排除对Nilablend™ 200G中尼卡巴嗪遗传毒性的担忧,需要阐明测试项目的作用机制。因此,FEEDAP专家小组无法确定用于评估消费者安全性的DNC的ADI。Nilablend™ 200G被认为通过吸入有毒,对眼睛有腐蚀性和刺激性,对皮肤有轻微刺激性,但不是皮肤致敏剂。吸入接触被认为对处理该添加剂的人员有风险。由于对DNC存在水生环境(淡水)的潜在风险,FEEDAP专家小组无法就Nilablend™ 200G对环境的安全性得出结论。Nilablend 200G的有效性已得到证实。